SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY 2024 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY BofA Securities Health Care Conference Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:Citizens JMP Life Sciences ConferenceFireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY2024 RBC Capital Markets Global Healthcare ConferenceFireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NYBofA Securities Health Care ConferenceFireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in Las V ...

Acadia Pharmaceuticals Inc. (ACAD) reported first-quarter 2024 earnings of 10 cents per share, beating the Zacks Consensus Estimate of 4 cents. In the year-ago quarter, the company had incurred a loss of 27 cents per share.The bottom line improved year over year owing to higher product sales.Acadia recorded total revenues of $205.8 million, which missed the Zacks Consensus Estimate of $206.9 million. Acadia’s net product revenues comprise revenues generated from the sale of its two marketed products, Nuplaz ...

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Corporate Participants Al Kildani - Senior Vice President, Investor Relations and Corporate Communications Steve Davis - President and Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Kimberly Manhard - Senior Vice President, Global Strategic Planning and Execution Mark Schneyer - Chief Financial Officer Conference Call Participants Tessa Romero - JPMorgan Ritu Baral - TD Co ...

First Quarter 2024 Earnings Call May 8, 2024 Call Agenda Welcome Al Kildani | Senior Vice President, Investor Relations and Corporate Communications CEO Opening Remarks Steve Davis | President and Chief Executive Officer Comme ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-50768 ACADIA PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 06-1376651 (State of Incorporation) (I.R.S. Employer Identification No.) 1 ...

Company Performance - Acadia Pharmaceuticals reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.04 per share, compared to a loss of $0.27 per share a year ago, representing an earnings surprise of 150% [1] - The company posted revenues of $205.83 million for the quarter ended March 2024, which missed the Zacks Consensus Estimate by 0.52%, but increased from $118.46 million year-over-year [1] - Over the last four quarters, Acadia has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [1] Stock Performance - Acadia shares have declined approximately 44.9% since the beginning of the year, contrasting with the S&P 500's gain of 8.8% [2] - The current Zacks Rank for Acadia is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [4] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.20 on revenues of $241.7 million, and for the current fiscal year, it is $0.62 on revenues of $967.9 million [4] - The trend of estimate revisions for Acadia is mixed, and changes in estimates for the coming quarters and current fiscal year are anticipated following the recent earnings report [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook [5] - Another company in the same industry, Biofrontera Inc., is expected to report a quarterly loss of $1.63 per share, reflecting a year-over-year change of +63%, with revenues projected at $11.52 million, up 32% from the previous year [5][6]

Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview - First quarter NUPLAZID® (pimavanserin) net product sales of $129.9 million - First quarter DAYBUE™ (trofinetide) net product sales of $75.9 million SAN DIEGO, CA, May 8, 2024 – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024. “In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% re ...

Industry Overview - The earnings season for the drug/biotech sector is concluding, with companies like Viatris and Perrigo set to report their first-quarter 2024 results this week [1] - 55% of companies in the Medical sector have reported quarterly earnings, with 93.9% beating earnings estimates and 75.8% exceeding revenue estimates [1] - Despite a year-over-year earnings decline of 31.2%, revenues in the Medical sector rose by 4.4% [1] Company Summaries Viatris - Viatris has a mixed performance history, beating earnings expectations in three of the last four quarters, with an average positive earnings surprise of 3.78% [3] - The company has an Earnings ESP of +0.74% and a Zacks Rank of 3, indicating a likely positive surprise, with consensus estimates of 68 cents per share in earnings and $3.74 billion in revenue [3] - Revenues in the Generic segment are expected to improve due to new products, offsetting declines in mature products [4] Perrigo Company - Perrigo has also shown mixed results, beating earnings expectations in three of the last four quarters, with an average beat of 6.47% [5] - The company has an Earnings ESP of 0.00% and a Zacks Rank of 4, with consensus estimates of 24 cents per share in earnings and $1.09 billion in revenue [5] - Sales in the Consumer Self Care Americas segment may be negatively impacted by lower net product sales in the U.S., while the Consumer Self Care International segment could benefit from acquisitions [5] Teva Pharmaceutical - Teva has a mixed earnings history, beating estimates in two of the last four quarters, with a trailing four-quarter average negative earnings surprise of 1.80% [7] - The company has an Earnings ESP of -4.46% and a Zacks Rank of 3, with consensus estimates of 51 cents per share in earnings and $3.7 billion in revenue [7] - Revenue growth is expected to be driven by higher sales of Austedo, despite lower sales from legacy brands [7] Iovance Biotherapeutics - Iovance has a mixed track record, beating estimates in two of the last four quarters, with an average beat of 20.05% [8] - The company has an Earnings ESP of 0.00% and a Zacks Rank of 3, with consensus estimates indicating a loss of 45 cents per share and $2.9 million in revenue [8] - Investors will be looking for updates on the commercial launch of its new melanoma drug, Amtagvi, during the earnings call [8] ACADIA Pharmaceuticals - ACADIA has a mixed earnings history, with an average earnings surprise of 18.56% over the last four quarters [9] - The company has an Earnings ESP of -71.34% and a Zacks Rank of 3, with consensus estimates of 17 cents per share in earnings and $206.9 million in revenue [9]

There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures. Several major pharmaceutical firms are grappling with patent cliffs, where key drug exclusivities are expiring. This opens the door for generic competition.Moreover, with the broader market presenting attractive investment options, holding on to these riskier pharma plays could result in significant opportunity cost. Many promising growth ...